We are ProQR, a company on a mission to create new medicines for patients in need. We focus on a group of diseases called rare diseases, with a very high need for new medicines. Out of the approximately 7,000 rare diseases, less than 400 have a treatment, and we intend to change that. To treat these diseases we use RNA therapies, a technology that allows us to address inherited diseases that are caused by a genetic defect. Our focus is on diseases that are very severe or life threatening, and have limited treatment options. Amongst others we work on the development of new medicines for several forms of inherited blindness such as Leberâs congenital amaurosis, Usher syndrome type 2 and autosomal dominant retinitis pigmentosa. Source
No articles found.
Syros is redefining the power of small molecules to control the expression of gene...
Syros is redefining the power of small molecule...
Cerus Corporation is dedicated solely to safeguarding the worldâs blood supply a...
Cerus Corporation is dedicated solely to safegu...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, le...
Intra-Cellular Therapies is a biopharmaceutical...
Proteon Therapeutics is working to deliver a new future for patients and families ...
Proteon Therapeutics is working to deliver a ne...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
PTC is a science-led, global biopharmaceutical company focused on the discovery, d...
PTC is a science-led, global biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.